Hyperbaric Oxygen Therapy for Ulcerative Colitis (HBOT-UC)

Overview

About this study

The purpose of this study is to determine the impact of HBOT (hyperbaric oxygen therapy) on clinical response/remission to medical therapy as measured bycomplete resolution of rectal bleeding (Mayo rectal bleeding sub-score of 0) and improvement in stool frequency (at least 1 point reduction in Mayo stool frequency sub-score), without the need for biologics, small molecules, or colectomy, by study day 5.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

- Participants with known or newly diagnosed UC who require hospitalization for an acute moderate to severe flare.

- Age 18-85.

- Consented and able to receive first HBOT session within first 48 hours of initiation of intravenous steroids.

Exclusion Criteria:

- Complication requiring urgent surgical intervention.

- Toxic megacolon.

- Inability to receive intravenous steroids.

- Historically failed 3 or more classes of advanced therapeutic options.

- Known or suspected diagnosis of Crohn's colitis, indeterminate colitis, ischemic colitis, radiation colitis, diverticular disease associated with colitis, microscopic
colitis or infectious colitis.

- Received any investigational drug within 30 days.

- Clinically significant cardiac, renal, neurological, endocrine, respiratory or hepatic impairment that increases the risk for HBOT toxicity.

- Women who are pregnant or nursing.

- Unwillingness to complete course of HBOT.

- Active SARS CoV 2 infection.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 12/14/23. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Laura Raffals, M.D.

Open for enrollment

Contact information:

Chad Rypstra

(507) 538-4289

Rypstra.Chad@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20559899

Mayo Clinic Footer